Surface Oncology

Cancer immunotherapies

SRF617 Clin2 solid cancers; NZV930 Clin1 multiple cancers (partner: Novartis); GSK4381562 Clin1 oncology (partner: GSK); SRF114 Clin1/Clin2 oncology

Surface Oncology is developing cancer therapies that function by targeting the immune-suppressive tumor microenvironment. Many cancer cells resist immune-cell clearance by fostering an immune-suppressive microenvironment. To overcome this, Surface Oncology is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to trigger a more robust immunologic response. Surface is researching four key areas of immune modulators that range from activating macrophages and natural killer cells, to blocking suppressive cell signaling molecules. This has enabled Surface to build their diverse pipeline with many products in Phase 1 trials for various cancers.